Exiting times for NattoPharma – Capital Markets Day on 5th of December

A split of the Company, highlighting both the major progress within the pharma business and the fantastic sales within the supplement business, will make the underlying value of the company more visible and thus create more shareholder value. 

"We are very happy to finalize the spin-off of the pharma company and believe in a success for PharmaCo, based on the strong data accumulated over years of investments in research and clinical studies," says Chairman Frode Bohan. 

"Sales of our supplement business continue to reach new, and record, levels, and the pharma business is progressing into a very exciting stage. The timing of the spin-off has been carefully planned", says CEO Daniel H. Rosenbaum. 

NattoPharma is pleased to invite investors, media and others to a Capital Markets Day and business update at KS Agenda, Haakon VIIs gate 9, 0161 Oslo on December 5th, 2017. 

The event will start with registration and coffee at 9:30, and the presentation will start at 10:00, followed by a light lunch directly therafter. 

If you would like to attend NattoPharmas CMD and business update, please register by email to CFO Kjetil Ramsøy,  kjetil.ramsoy@nattopharma.com

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.

Subscribe

Documents & Links